Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamibarotene (OMS0728) in relapsed or refractory acute promyelocytic leukemia
ChiCTR-IPR-15005943Phase 3Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tamibarotene in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Complete remission rate. Started Dec 2010; status: recruiting.
02
Drugs
tamibarotene
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR-IPR-15005943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15005943.